Table 1 Data of all patients and of subjects grouped by a titre of antibodies to surface antigen of hepatitis B virus ≤ 10 UI/L (Group I) and > 10 UI/L (Group II)
Parameter | All patients N = 518 | Group I n = 207 | Group II n = 311 | P value for analysis between groups I and II |
|---|---|---|---|---|
Men, n (% of all) | 290 (56.0) | 110 (53.1) | 180 (57.9) | 0.320 |
Age, years | 62.5 ± 15.5 | 64.8 ± 14.9 | 60.9 ± 15.8 | 0.004 |
RRT duration, years | 1.82 (0.002 – 26.1) | 1.24 (0.04 – 23.8) | 2.71 (0.002 – 26.1) | 0.001 |
Diabetic nephropathy, n (% of all) | 141 (27.2) | 72 (34.8) | 69 (22.2) | 0.002 |
Chronic glomerulonephritis, n (% of all) | 86 (16.6) | 22 (10.6) | 64 (20.6) | 0.003 |
Hypertensive nephropathy, n (% of all) | 84 (16.2) | 34 (16.4) | 50 (16.1) | 1.000 |
Chronic tubulointerstitial nephritis, n (% of all) | 60 (11.6) | 24 (11.6) | 36 (11.6) | 1.000 |
History of acute hepatitis, n (% of all) | 23 (4.4) | 6 (2.9) | 17 (5.5) | 0.195 |
Positive HBsAg, n (% of all) | 16 (3.1) | 13 (6.3) | 3 (1.0) | 0.001 |
Positive HBV DNA, n (% of all HBsAg positive) | 16 (100.0)* | 13 (100.0) | 3 (100.0) | 1.000 |
Positive anti-HBc, n (% of all) | 128 (24.7) | 30 (14.5) | 98 (31.5) | < 0.0001 |
Isolated positive anti-HBc, n (% of all anti-HBc positive) | 17 (13.3) | 17 (56.7) | 0 (0.0) | < 0.0001 |
Full vaccination series against HBV with developed anti-HBs titre > 10 IU/L in anti-HBc negative patients, n (% of all anti-HBc negative patients) | 213 (54.6) | 0 (0.0) | 213 (100.0) | < 0.0001 |
Positive anti-HCV, n (% of all) | 55 (10.6) | 20 (9.7) | 35 (11.3) | 0.663 |
Positive HCV RNA (n, % of all examined anti-HCV positive) | 32 (58.2) | 9 (45.0) | 23 (65.7) | 0.163 |
ALT (U/L) | 13 (0.6 – 209) | 14 (0.6 – 126) | 13 (2 – 209) | 0.392 |
AST (U/L) | 14 (4 – 177) | 14 (5–97) | 14.5 (4 – 177) | 0.570 |
GGT (U/L) | 27 (0 – 498) | 28 (5 – 308) | 26 (0 – 498) | 0.757 |